NOVO — Marts 2026
-
Ad PN 16:47 - Så FDA kritiserer Novos bivirknings-systemer i denne tid, hvor semaglutid eksploderer globalt. Har Novo ikke styr på det? PS Novo fik observationerne i feb 2025 og har haft omkring et år (!) til at adressere dem, før FDA valgte at sende et egentligt advarselsbrev. Er det normalt? Og besynderligt, at modsat Novo, så kunne FDA identificere afdøde….
-
Novo USA Statement vedr FDA https://www.novonordisk-us.com/media/news-archive/news-details.html
-
Grupo Santander has initiated coverage of $NVO with an Outperform rating.
The bank also sets a price target of DKK 366.84.
-
Olieprisen eksploderer efter USA's angreb i Iran, og frygten rammer aktiemarkedet. Hansen og Larsen analyserer, hvorfor Zealand Pharma og Gubra falder på gode data, og om Novo Nordisk har lavet en fejl med HIMS-aftalen. Hør om alt dette og meget mere i denne uges afsnit af Investeringspodcasten. https://proinvestor.com/boards/131498
-
New study reveals surprising benefit of GLP-1s that has nothing to do with weight loss https://www.unilad.com/news/health/study-glp-1s-benefit-alcohol-addiction-568519-20260308?utm_medium=Social&utm_source=Facebook&fbclid=IwY2xjawQebl1leHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeAAmYhLNm-DXp9ytGDHnNy0VGqkkXhU5OMYFNMwpkAZZvndMViN1zzYMuxkg_aem_R2UuYhsKFbIr6J
D4llIwsw -
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum? https://www.zacks.com/stock/news/2882175/can-novo-nordisks-hims-hers-deal-revive-its-glp-1-momentum
-
Novo-ejer må se formuen dykke med 366 mia. kr. https://proinvestor.com/investornyt/1420536/novo-ejer-ma-se-formuen-dykke-med-366-mia-kr
-
Obesity Drugs Are Getting Easier and Cheaper to Find
More apps, new markets and novel compounds will further ease access.https://www.bloomberg.com/news/newsletters/2026-03-12/obesity-drugs-are-getting-easier-and-cheaper-to-find?taid=69b295cee4ff750001000fbe&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter -
Novo/Eli Lilly: Nu bliver compounded et lille niecheprodukt https://proinvestor.com/boards/131511
-
Kort video: Amylin er ikke færdig inden for fedme - tværtimod | Zealand Pharma, Gubra, Novo Nordisk https://proinvestor.com/boards/131518
-
Wegovy portfolio growth shifts to the pill as injectable sales forecast to plateau https://www.pharmaceutical-technology.com/analyst-comment/wegovy-portfolio-growth-pill/
-
Godmorgen
-
Novo: Tabel med recepttal for Wegovy-pillen https://proinvestor.com/investornyt/1421010/novo-tabel-med-recepttal-for-wegovy-pillen
-
Novo Nordisks Wegovy-pille fortsætter frem målt på recepttal i USA - positivt momentum mener analytiker https://proinvestor.com/investornyt/1421022/novo-nordisks-wegovy-pille-fortsaetter-frem-malt-pa-recepttal-i-usa-positivt-momentum-mener-analytiker
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind